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SUMMARY 
Objectives 
A population based study was undertaken to determine the mortality and morbidity for people 
with hypoparathyroidism compared to the general population.  
Methods 
In this study, patients identified with chronic hypoparathyroidism using data-linkage from 
regional datasets were compared to five age and gender matched controls from the general 
population.  Data from biochemistry, hospital admissions, prescribing and the demographic 
dataset were linked.  Outcomes for mortality and specified conditions were examined for all 
patients and sub-divided into post-surgical and non-surgical cases of hypoparathyroidism.  
Results 
All patients had an increased risk of epilepsy (HR 1.65 (95% CI 1.12-2.44)) and cataracts 
(HR 2.10 (1.30-3.39)) but no increased fracture risk.  Only non-surgical hypoparathyroid 
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patients also had increased mortality (HR 2.11 (1.49-2.98), cardiovascular disease (HR 2.18 
(1.41-3.39), cerebrovascular disease (HR 2.95 (1.46-5.97), infection (HR 1.87 (1.2-2.92) and 
mental illness (HR 1.59 (1.21-2.11).    There was an increased risk of renal failure (HR 10.05 
(95% CI 4.71-21.43)) during the first 2000 days (5.5 years) of follow up.  Renal failure and 
death was associated with increasing serum calcium concentrations.  
Conclusion  
Patients with hypoparathyroidism have an increased risk of cataract and epilepsy.  Non-
surgical hypoparathyroidism is associated with increased mortality and additional 
morbidities.   
Key words: Calcium, Parathyroid-related disorders, Health Services Research, Statistical 
Methods, Epidemiology, Hypoparathyroidism, Morbidity 
 
INTRODUCTION 
Hypoparathyroidism is a rare disorder characterised by low serum calcium and abnormally 
low concentration of parathyroid hormone (PTH) (1,2). Hypoparathyroidism may be 
transient, such as after neck surgery, or may be chronic due to accidental removal of, or 
permanent damage to the parathyroid glands from surgery (3). Post-surgical 
hypoparathyroidism is the commonest cause of hypoparathyroidism, occurring in 2-5% long-
term surgical neck explorations (4-6). We have recently reported a prevalence of primary 
hypoparathyroidism in Tayside, Scotland of 40 per 100,000 (7) similar to the rate observed in 
the US at 37 per 100,000 (8) but greater than that seen in other European studies at 10-24 per 
100,000 (9, 10, 11).  The rate was 23 and 17 per 100,000 respectively for post-surgical and 
non-surgical (7). The rate of post-surgical cases is similar across studies from 22 to 29 per 
100,000 (7, 8, 10) although lower in Norway at 10 per 100,000 (11).   The rate of non-
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surgical cases was more variable from 2.3 (9) to 8 (8) to 17 (7) per 100,000.  Our 
methodology however is likely to be more sensitive at identifying patients with milder 
hypoparathyroidism who may be missed using methods depending on hospital referral and 
patient registries.   
Morbidities associated with hypoparathyroidism are either related directly to low calcium or 
raised phosphate concentrations or indirectly via treatment for the disorder which comprise 
oral calcium and vitamin D analogue supplements (4, 12). In addition, some of the non-
surgical cases are likely to be due to genetic mutations e.g DiGeorge syndrome, which are 
known to be associated with congenital heart defects and urogenital abnormalities (13).  
Other autoimmune aetiologies e.g. autoimmune polyglandular syndrome are associated with 
Addisons disease and thyroid disease potentially placing patients at risk (14,15).  
Conventionally, the aim of treatment has been to maintain the serum calcium concentration 
around the lower limit of the reference range.  This limits the risks of hypercalciuria and 
hypercalcaemia with the resultant risks of symptoms, renal stones, and other complications. 
Previous studies have reported association between renal complications and 
hypoparathyroidism (10, 16). The Danish national studies reported that patients with 
hypoparathyroidism had an increased risk of seizure, depression, neuropsychiatric diseases 
and infections, whereas there was no increased risk of cardiovascular disease, cataract, 
fracture or death (10, 17).     
The aim of this study was to investigate if patients with chronic hypoparathyroidism had an 
increased risk of incident cataract, cardiovascular disease, cerebrovascular disease, infections 
of skin and chest, epilepsy, fracture, mental health, renal failure and death. 
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MATERIALS AND METHODS 
Patients and controls 
All Tayside residents registered with a general practice in Scotland are assigned to a unique 
10-digit health index, known as a Community Health Index (CHI). CHI is used as a patient 
identifier that facilitates the linkage of all health care-related records. All such records are 
held and linked at the Health Informatics Centre (http://www.dundee.ac.uk/hic) of the 
University of Dundee. We have previously identified adult patients (age 18years and over) 
between January 1988 and August 2016 with hypoparathyroidism using four principle 
anonymous patient-level datasets, and the patient selection and classification process is 
described in detail in Vadiveloo et al. (7). In brief, patients were identified from the Tayside 
population based on at least three out-patient based measurements of serum albumin-
corrected calcium below the reference range (<= 2.15mmol/L) with a minimum of a one-
month interval between measurements. All calcium measurements taken as an in-patient were 
excluded, 94% of patients had a serum calcium below 2.10 mmol/L and 83% of patients had 
low serum calcium at least 6 months apart. In addition, patients have had one of the following 
1) neck surgery or irradiation prior to hypocalcaemia or admission with hypoparathyroidism, 
2) low or inappropriately normal plasma parathyroid hormone (PTH) while having low 
calcium (<5pmol/L) or 3) on three or more prescriptions per year treatment with Calcium 
and/or cholecalciferol or activated Vitamin D. Exclusion criteria included 1) patients with 
high PTH while having low calcium; 2) patients with serum 25-OH Vitamin D less than 50 
nmol/L while having low calcium; 3) patients who had less than three low calcium 
concentration after excluding calcium measurements taken during admission; 4) patients who 
had low calcium concentrations, all within 1 month; 5) patients who had either serum 
creatinine > 200µmol/L or eGFR < 20 prior to the first recording of a low serum calcium. 
Using an electronic-based algorithm to identify patients across the community is different to 
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previous approaches, but arguably identifies patients missed when depending on referrals to a 
specialist and registration on specific databases, especially non-surgical cases.  These issues 
have been discussed elsewhere (7).  Our patients were sub-categorised as having post-
surgical hypoparathyroidism, or having non-surgical hypoparathyroidism (7) or having 
hypoparathyroidism associated with hypomagnesaemia (<0.5mmol/l: lower limit of local 
reference range is 0.69mmol/l).  This last group was assessed separately as some of these 
patients will have had hypomagnesaemia due to hypoparathyroidism, but some will have had 
hypomagnesaemia causing the hypocalcaemia, and may not truly have hypoparathyroidism. 
Drugs which can cause hypomagnesaemia and lower serum calcium include diuretics and 
proton pump inhibitors, which are markers of confounding co-morbidities such as heart 
failure and may have influence the outcomes. 
In this study, a group of controls from the general Tayside population who had serum calcium 
concentration within the laboratory reference range were identified and were matched to 
cases with hypoparathyroidism. For each patient with hypoparathyroidism, five controls were 
randomly selected, matched by gender, age (± 5 years) and diabetes status. Each comparator 
was assigned an index date (start of follow-up) identical to the date of diagnosis for 
hypoparathyroidism of the case.  Date of diagnosis was defined as the first low calcium 
measurement. 
 
Databases and data validity 
Tayside population demographic database  
This served as a master index to provide information on gender, date of birth, date of death, 
and dates registered with general practitioner. This information was obtained from the 
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National CHI register and contained 99% of the population. This was validated by the 
external systems before it reached the Health Informatics Centre. 
 
Scottish morbidity record 1 (SMR01) 
The SMR01 dataset was used to obtain information on morbidity. This dataset consisted of 
hospital admission data routinely validated and collated by the Information and Statistics 
Division of the National Health Service in Scotland 
(http://www.isdscotland.org/isd/2737.html). The International Classification of Diseases 
(ICD) ninth and 10th revision codes are used in the SMR01 to classify all hospital inpatient 
episodes.  
 
Tayside prescription database 
This contained all prescriptions dispensed from all community pharmacies in Tayside. Each 
entry comprised the patient’s anonymized CHI, prescription date, drug name, formulation, 
dosage, frequency, and duration. These data were received from Practitioner Services 
Divisions and we were given access to all prescriptions for anti-epileptic, ant-depressant and 
anti-psychotic medications. 
 
Biochemistry database 
The biochemistry database contained information on serum calcium, parathyroid hormone 
concentrations and vitamin D concentrations which were used to define the cohort as 
described previously (7).  eGFR measurements were also available to define renal failure. 
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Each entry comprised the patient’s anonymized CHI, the test performed, date, and the results. 
These data were received directly from the lab systems and were validated routinely. 
 
Statistical methods 
The following outcomes of all patients with hypoparathyroidism were identified: cataract, 
cardiovascular disease, cerebrovascular disease, infections of skin and chest (e.g cellulitis and 
pneumonia), epilepsy, fracture, mental health, renal failure and death. SMR01, the admission 
database was used to identify all the above outcomes. Patients who had epilepsy and mental 
health problem were also identified using the prescribing database. Patients who had renal 
failure were identified using the eGFR measurements in the biochemistry database. Renal 
failure was defined as eGFR below 30ml/min. Survival analysis was used to follow up 
patients until an event occurred, they were censored or the end of the study. Cox proportional 
hazards model was used to model the data, and the assumption of proportional hazards was 
assessed using the graphical and numerical methods of Lin, Wei and Ying (1993).   These 
methods are derived from cumulative sums of martingale residuals over follow-up times or 
covariate values. Non-proportional hazard model was used if there was a violation in the 
proportional hazard assumption. The outcomes of hypoparathyroid patients were compared 
with five matched controls (age and gender) from the Tayside population.  The association 
between mean calcium concentration after diagnosis and all the outcomes were also 
investigated. All analyses were performed on anonymized datasets using IBM SPSS Statistics 
22 and SAS 9.4. 
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Other confounders 
Apart from gender and age, other covariates adjusted for in the survival analysis were 
socioeconomic deprivation and previous history of the disease studied. 
 
Ethical approval 
The study was approved by the Tayside Medical Ethics Committee and data protection by the 
Tayside Caldicott Guardians.  
 
RESULTS 
There were a total of 280 patients with chronic hypoparathyroidism, of which 116 cases were 
post-surgical, 58 cases had hypomagnesaemia and 106 cases were non-surgical (7).  The total 
follow-up period was 2587 years with a median of 9 years. Overall, 30.7% of the cases were 
male, and the mean age was 51.6 years (SD 19). The baseline characteristics of 
hypoparathyroid cases and reference population are shown in Table 1. At baseline, 
significantly higher percentages of hypoparathyroid cases had pre-existing infections 
(p<0.001), cardiovascular disease (p=0.001), fractures (p=0.004), mental health conditions 
(p<0.001) and renal failure (p<0.001) compared to the reference population.  
There was no violation of the assumption of proportional hazards in all outcomes except for 
renal failure. A proportional hazards model was used to assess all outcomes except for renal 
failure when a non proportional hazard model was used. Table 2 shows the unadjusted and 
adjusted hazard ratios (HR) for inpatient admissions due to cataract, cardiovascular disease, 
cerebrovascular disease, infection, epilepsy, fracture, mental health and death. The total 
number of events for each disease studied were; cardiovascular disease (n=251), 
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cerebrovascular disease (n=84), cataract (n=137), epilepsy (n=163), infection (n=263), 
fracture (n=191), mental health (n=619), renal failure (n=149) and death (n=375). Of patients 
who had an epileptic fit, only two had a serum calcium less than 2mmol/L within one month 
of the fit.  Compared with the reference population, patients with chronic hypoparathyroidism 
were associated with an increased risk of cardiovascular disease, cerebrovascular disease, 
cataract, epilepsy, infection, mental health and death. As a sensitivity analysis, when all 
patients with a serum albumin less than 30 g/L, were excluded, which is a marker of chronic 
ill health, the adjusted mortality rate remained significant with a hazards ratio of 1.44 (1.02-
2.02; p=0.037).   There were no significant differences in the risk of fracture between 
hypoparathyroid patients and the matched reference population. When the hypoparathyroid 
patients were grouped into two categories, patients in the post-surgical group had a 
significantly increased risk of cataract and epilepsy compared with the reference population.  
However, those in non-surgical group had increased risk of cardiovascular disease, 
cerebrovascular disease, epilepsy, infection, mental health and death compared with the 
reference population.  Those with hypomagnesaemia associated hypoparathyroidism had 
increased risk of cardiovascular disease, cataracts, infection, fractures mental health and 
death.  This risk profile is similar, but not identical to those with non-surgical 
hypoparathyroidism, but the hazards ratios seem to be greater for the hypomagnesaemia 
group. 
The cumulative martingale residuals plots showed that the proportional hazard assumption 
was violated for all cases and non-surgical cases whereby, the true hazard ratio for renal 
failure was changing over time. The hazard ratio was found changing at 2000 days after 
baseline for the non-surgical group, therefore the follow-up time from baseline was split for 
the overall group and this sub-group ; ≤2000 days and > 2000 days. The Table 3 shows the 
unadjusted and adjusted hazard ratios (HR) for renal failure. Compared to the reference 
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population, hypoparathyroid patients had significantly higher risk of renal failure within the 
first 2000 days from their first low calcium (baseline). The risk of renal failure was no longer 
significant in patient with hypoparathyroidism after 2000 days from baseline.  The risks of 
renal failure in post-surgical and hypomagnesaemia patients were significantly higher 
throughout the study period. However, the risk in non-surgical patient were only significantly 
higher within the first 2000 days from baseline.  
Table 4 show that serum calcium concentration was positively associated with renal failure 
and death, but otherwise mean serum calcium was not associated with any of the outcomes. 
 
DISCUSSION 
In this study, we demonstrated an increased death rate with increased risk of cardiovascular 
disease, cerebrovascular disease, cataract, epilepsy, infection, mental illness, renal failure in 
all patients with hypoparathyroidism when compared to the matched controls.  For patients 
with post-surgical hypoparathyroidism we demonstrated an increased risk of cataract, 
epilepsy and renal failure only and no increased mortality. However, patients with non-
surgical hypoparathyroidism had an increased risk of death, cardiovascular disease, 
cerebrovascular disease, epilepsy, infection, mental illness and renal failure.  There was no 
increased risk of fractures in either group.  The hypomagnesaemia group should similar risks, 
but lacking the risks of cerebrovascular disease and epilepsy but additional risk of fracture. 
The increased risk of fracture is notable given no trends for this in the other two sub-groups 
and is likely to represent a confounding variable relating to the increased age, existence of 
diabetes and likely increased frailty of this sub-group. The higher hazards ratios for those 
with hypomagnesaemia may reflect the lower numbers in this group or may also reflect 
increased frailty. Our results are remarkably similar to those observed from Denmark, where 
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there was an increased risk of all the same outcomes with no risk of fractures in non-surgical 
hypoparathyroidism (9). The Danish study showed a borderline increased risk mortality in 
non-surgical hypoparathyroidism which did not quite reach statistical significance (HR 1.25, 
p=0.06) (9) but no increased mortality for post-surgical cases (10). In addition to an increased 
risk of renal failure and seizures for patients with post-surgical hypoparathyroidism, the 
Danish study also showed a risk for mental illness and infection (10, 17), although they did 
not demonstrate any risk for cataracts unlike our study.  They had a greater number of 
patients and may have been better powered to demonstrate these end points which showed a 
non-significant trend in our study.   
 
Our Scottish cohort and the Danish cohort are the only two reported population-based case 
controlled follow up studies in hypoparathyroidism that we are aware of.  It is an important 
finding that our data confirmed the previous findings, but also showed a two-fold increased 
death rate in patients with non-surgical hypoparathyroidism, a finding which did not quite 
reach significance in the previous study.  In addition our study was able to provide a 
simultaneous comparison between post-surgical and non-surgical cases and 
hypomagnesaemia cases.  It is likely that the vast majority of the group with 
hypomagnesaemia are non-surgical cases, and they demonstrated greatest risk for death and 
most (but not all) outcomes measured, although they may be confounded by co-existing co-
morbidities.  There was also a greater risk for people with non-surgical hypoparathyroidism 
(normal magnesium concentrations) compared to those with post-surgical 
hypoparathyroidism.  As post-surgical cases occur acutely and not insidiously they are more 
likely to be recognised early and referred to a specialist clinic where they may get better long-
term care.  Non-surgical cases may be linked with other co-existing conditions such as 
Addison’s disease and other autoimmune disease or genetic disorders which may add to their 
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risk.  We should be encouraging all cases of persistent hypocalcaemia to be referred to a 
specialist clinic so that all these issues can be addressed. 
Others have shown increased morbidity with high rates of renal failure, renal and basal 
ganglia calcification (16), along with poor quality of life and heightened anxiety scores (11), 
mental illness (18) and reduced employability (19).  These outcomes have been highlighted in 
reviews on the outcomes of hypoparathyroidism (4, 20).   
We have previously described a high prevalence of hypoparathyroidism in a population based 
study at 40-47 per 100,000 (7) with a particularly high rate of non-surgical 
hypoparathyroidism at 17 per 100,000 (7).  It is thus important to note the high levels of 
morbidity especially in the non-surgical cases, if the prevalence of this condition is higher 
than previously thought.  This may not be a surprise as many patients with non-surgical 
hypoparathyroidism will have had auto-immune causes or genetic causes with associated 
additional morbidities sometimes requiring additional medications such as corticosteroids.  
Our results highlight the long-term morbidity associated with hypoparathyroidism which is 
often unrecognised by clinical staff, as well as short term complications of managing the 
hypocalcaemia (12, 16, 19). 
Serum calcium concentrations were directly associated with renal failure and death as was 
observed by Mitchell et al (16).  Mean serum calcium concentration was not associated with 
any of the other outcomes, and neither was calcium/phosphate product (data not shown).  
Mean serum calcium or phosphate concentration from six months after diagnosis is a fairly 
crude measure of biochemical control, and may not reflect subtle changes in calcium 
concentration, which may be important in determining the outcomes assessed, and our study 
may be underpowered.  Unfortunately, reliable data on urinary calcium excretion was not 
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available in this population-based study.   Variability in serum calcium or phosphate 
concentration may also be a factor in determining outcomes that we have not measured. 
The mechanisms causing the adverse outcomes are not well studied.  Due to a high 
calcium/phosphate product associated with hyperphosphataemia it is thought that calcium 
phosphate crystals get deposited in the lens of the eye causing cataract (21) and this may also 
contribute to arteriosclerosis precipitating cardiovascular and cerebrovascular disease, 
although chronic hypocalcaemia may also contribute to cardiomyopathy (22) and 
arrhythmias.  Increased renal failure is also likely to be due to deposition of calcium 
phosphate.  Although hypoparathyroidism is a state of low bone turnover with increased bone 
density (23), this study and previous study (9) did not show an overall increased risk of any 
fractures. However, an increased risk of forearm fractures has been reported (9).  It is difficult 
to explain the reason for increased neuropsychiatric disease, epilepsy and infection, although 
the ubiquitous effect of intracellular calcium stabilising cell membranes may be relevant. 
Limitations of the study include small numbers of patients (n=280) due to the rarity of the 
condition, but some end points may be under powered.  In addition we did not have data on 
cancer outcomes or forearm fractures, which may be at increased risk in parathyroid disease.  
It is possible that we may have missed some well controlled patients who had normal serum 
calcium throughout. However, our prevalence rates were greater than those previously 
reported in the literature which is reassuring that it is unlikely that we missed large numbers 
of patients. We also excluded patients with low serum Vitamin D concentrations to avoid 
being criticised for inappropriate inclusion, but this also creates a potential weakness, which 
may have resulted in an under-estimate of the morbidity recorded.  Unfortunately we did not 
have detail on the causes of non-surgical hypoparathyroidism and could not distinguish 
between genetic, autoimmune and other causes.  Additionally we could not be sure whether 
the group with hypomagnesaemia had low serum magnesium due to the hypoparathyroidism 
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or whether the hypomagnesaemia was the driving cause of the hypocalcaemia.  This is the 
reason this group was analysed separately, as the latter group would include patients on 
medications e.g. diuretics and proton pump inhibitors which are markers of other 
confounding co-morbidities such as cardiac failure. It is possible to purchase calcium and 
non-activated Vitamin D over the counter and we were unable to account for such 
prescriptions.  As all prescriptions in Scotland are free this may be less of an issue compared 
to some countries.  A further limitation is that the date of inclusion into our study may not be 
the actual date of diagnosis, if diagnosis occurred some before the start of the study.  
Conversely however, if there were delays in referral to a specialist, our study would identify 
the true date of the first low serum calcium which may be years before a specialist makes a 
formal diagnosis.  The strength of this study include that it is a true population based study 
where patients in both primary and secondary care settings were identified (7).  Our study 
will include patients potentially missed using registry based studies as discussed in detail 
elsewhere (7), especially patients with milder hypocalcaemia. Patients with vitamin D 
deficiency were excluded, but if we have erroneously included some patients with milder 
hypocalcaemia it is likely to have reduced the likelihood of any positive findings.  However 
the outcomes for non-surgical hypoparathyroidism were worse than those for post-surgical 
cases.   The use of prescribing data has helped identify patients with mental illness and 
epilepsy.   
The results from our study and others indicate that the outcomes for hypoparathyroidism are 
not ideal.  Some complications may be related to chronic hypocalcaemia, whilst others may 
relate to relative overtreatment and chronic hypercalcaemia.  All patients with persistent 
hypocalcaemia should get referred to a specialist clinic where they should be fully evaluated 
and may get better long-term care, and hopefully improved outcomes. The outcomes of death 
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and renal failure seem to be associated with higher concentrations of serum calcium, 
suggesting the latter as a more significant issue for chronic complications.  .   
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